News & Updates
Filter by Specialty:
Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke
29 Feb 2024
Use of CYP2C19 genotype-guided antiplatelet therapy with cilostazol or ticagrelor as a substitute to clopidogrel is more cost-effective than conventional antiplatelet therapy for patients with acute minor ischaemic stroke and high-risk transient ischaemic attack, suggests a China study.
Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke
29 Feb 2024TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
29 Feb 2024
byAudrey Abella
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.